Abstract Number: 0108 • ACR Convergence 2023
Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database
Background/Purpose: Electronic health record (EHR) data provide an inexpensive, information-rich tool to study rare diseases like antiphospholipid syndrome (APS). Many such studies rely on structured…Abstract Number: 1605 • ACR Convergence 2023
Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: Recent studies implicate complement activation in the pathophysiology of antiphospholipid syndrome (APS), especially in patients with severe manifestations, such as catastrophic APS (CAPS). This…Abstract Number: 0109 • ACR Convergence 2023
Persistent Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome
Background/Purpose: Inappropriately amplified inflammatory responses are hallmarks of many diseases, with extracellular ATP often playing a central role in the orchestration of inflammation. Regulated cellular…Abstract Number: 1606 • ACR Convergence 2023
Purinergic Signaling as a Potential Therapeutic Target for APS Thromboinflammation
Background/Purpose: In first responding cells such as neutrophils and platelets, extracellular ATP released from activated or dying cells engages cell-surface receptors to launch proinflammatory and…Abstract Number: 0110 • ACR Convergence 2023
Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss
Background/Purpose: Antiphospholipid antibodies (aPL) induce obstetric complications associated with placental insufficiency by promoting trophoblast dysfunction and inflammation at the maternal-fetal interface. Neutrophils have been found…Abstract Number: 1607 • ACR Convergence 2023
Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus
Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…Abstract Number: 0111 • ACR Convergence 2023
Hippo-YAP1-CCN2 Signaling by Microvascular Endothelial Cells Licenses Vascular Smooth Muscle Cell Proliferation in Antiphospholipid Syndrome
Background/Purpose: Some patients with antiphospholipid syndrome (APS) are afflicted by an insidious small-vessel vasculopathy that results in the accrual of organ damage over time. While…Abstract Number: 1608 • ACR Convergence 2023
Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…Abstract Number: 0674 • ACR Convergence 2022
Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies
Background/Purpose: Thrombosis and thrombocytopenia are defining characteristics of antiphospholipid syndrome (APS), but can also be seen in heparin-induced thrombocytopenia (HIT). Hospitalized patients with APS are…Abstract Number: 0690 • ACR Convergence 2022
The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis
Background/Purpose: Malleable metabolic pathways guide both productive and pathological neutrophil functions, including neutrophil extracellular trap release (NETosis). NETosis plays an important role in APS pathophysiology.…Abstract Number: 0675 • ACR Convergence 2022
Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort
Background/Purpose: Antiphospholipid syndrome (APS) is associated with diffuse alveolar hemorrhage (DAH). However, only case reports and small case series are available in the literature. We…Abstract Number: 0691 • ACR Convergence 2022
Structural Differences Exist in Beta-2-Glycoprotein I from APS Patients Compared to Healthy Controls
Background/Purpose: Beta-2-Glycoprotein I (B2GPI) is a serum protein of approximately 50kDa and is the main autoantigen of Antiphospholipid syndrome (APS). Antibodies to B2GPI (aB2GPI) are…Abstract Number: 0676 • ACR Convergence 2022
Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature
Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with antiphospholipid syndrome (APS) and adrenal hemorrhage (AH).Methods: We performed a multicenter retrospective cohort…Abstract Number: 0692 • ACR Convergence 2022
The Interplay Between Lipid Peroxidation and Neutrophil Extracellular Trap (NET) Formation in APS Pathogenesis
Background/Purpose: Lipid peroxidation is the result of disrupted redox homeostasis and functions as a key component in various cell death programs. Neutrophil extracellular trap (NET)…Abstract Number: 0677 • ACR Convergence 2022
Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
Background/Purpose: Obstructive sleep apnea (OSA) has been associated with an increased risk of thrombotic-related events, such as myocardial infarction and cerebrovascular diseases in the general…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 19
- Next Page »